 |
|
|
| |
Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4a Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients
|
| |
| |
Reported by Jules Levin
AASLD San Francisco 2011 Nov 6-9
Amelia S. Petry1, Iain P. Fraser1, Kristien Van Dyck1, Robert B. Nachbar1, Inge De Lepeleire1, Martine Robberechts1, Lingling Han1, John Palcza1, Valentine S. Moiseev2, Zhanna D. Kobalava2, Markus Uhle3, Frank Wagner3, Edward O'Mara1, John A. Wagner1
1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 2ASCENT Clinical Research Solutions OOO, Moscow, Russian Federation, 3Charité Research Organization GmbH, Berlin, Germany
|
| |
|
|
|
|
|
